ENORAMA PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.47 SEK | +5.11% |
|
+0.82% | -20.32% |
| 05-22 | Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | 12.8M 1.23M 96.22M | Sales 2022 | 6.85M 657K 51.47M | Capitalization | 28.05M 2.69M 211M |
|---|---|---|---|---|---|
| Net income 2021 | -27M -2.59M -203M | Net income 2022 | -42M -4.03M -316M | EV / Sales 2021 | 12.7 x |
| Net cash position 2021 | 8.41M 808K 63.23M | Net cash position 2022 | 2.23M 214K 16.76M | EV / Sales 2022 | 3.77 x |
| P/E ratio 2021 |
-4.97
x | P/E ratio 2022 |
-0.68
x | Employees | 9 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 35.2% |
More Fundamentals
* Assessed data
More news
| 1 day | +5.11% | ||
| 1 week | +0.82% | ||
| Current month | +6.01% | ||
| 1 month | -16.55% | ||
| 3 months | -57.12% | ||
| 6 months | -29.23% | ||
| Current year | -20.32% |
1 week
2.27
2.69
1 month
2.203.50
Current year
2.0010.50
1 year
2.0010.50
3 years
2.0043.85
5 years
2.00110.00
10 years
2.00177.00
| Managers | Title | Age | Since |
|---|---|---|---|
Annette Agerskov
CEO | Chief Executive Officer | 64 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 61 | 31/12/15 | |
| - | - | ||
Daniel Schroeder
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/06/24 | 2.47 | +5.11% | 8,087 |
| 03/06/24 | 2.35 | +0.86% | 3,282 |
| 31/05/24 | 2.33 | 0.00% | 9,423 |
| 30/05/24 | 2.33 | -2.92% | 22,271 |
| 29/05/24 | 2.4 | -2.04% | 42,671 |
Delayed Quote Nasdaq Stockholm, June 04, 2024 at 04:04 pm
More quotes
Enorama Pharma AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company is mainly focused on the development of medical chewing gum that contains drugs. The Company's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The Company distributes its products in Europe through pharmacy chains and grocery stores.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.32% | 9.67M | |
| +15.41% | 41.07B | |
| +23.48% | 22.65B | |
| +18.48% | 14.14B | |
| +50.90% | 12.09B | |
| -0.05% | 6.79B | |
| -10.77% | 6.91B | |
| -8.87% | 5.73B | |
| +15.28% | 5.59B | |
| +4.00% | 4.82B |
- Stock Market
- Equities
- ERMA Stock